The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) begins with benign steatosis caused by ectopic storage of triacylglycerols in the liver. Persistent steatosis, in combination with other genetic and environmental factors, leads to nonalcoholic steatohepatitis (NASH) characterized by functional impairment, inflammation, and fibrosis. However, it remains unclear how persistent steatosis directly contributes to the progression of NAFLD, which may represent a therapeutic target. The organ-on-a-chip (OOC) has emerged as a new culture platform to recapitulate human pathological conditions under which drug candidates can be screened. Here, we developed a simple OOC steatosis model using the Mimetas OrganoPlate with a human liver cell line, HepG2. Treating the HepG2 OOCs with fatty acid overload induced steatosis within 24 h. Moreover, persistent steatosis for 6 days impaired OOC viability and hepatic function, as measured by a WST-8 assay and albumin production, respectively. Lastly, the HepG2 OOCs were exposed to drugs being tested in clinical trials for NAFLD/NASH during the 6-day period. Pioglitazone improved the OOC viability while elafibranor reduced the steatosis in association with reduced viability and albumin production. In conclusion, we show that the HepG2 steatosis OOC model is a useful tool on which the efficacy and toxicity of various therapeutic candidates can be tested.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study showed that pioglitazone and elafibranor exhibited fundamentally different effect–safety profiles. Pioglitazone improved viability, while elafibranor reduced steatosis but was accompanied by a decrease in functional parameters.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In more complex systems (3D cultures, co-cultures), lower FFA concentrations (10–500 μM) are required [131,132,133,134], which brings conditions closer to physiological ones and reduces the risk of non-specific cytotoxicity.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For pharmacological “effect–safety” evaluation, 3D organ-on-a-chip platforms [131] provide a unique opportunity to simultaneously assess the therapeutic efficacy and toxicity of candidates, which is unattainable in 2D.”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Modeling physiological events in 2D vs. 3D cell culture
Duval, K., Grover, H., Han, L.-H., Mou, Y., Pegoraro, A. F., Fredberg, J., & Chen, Z. (2017) · Physiology · doi:10.1152/physiol.00036.2016 · Cited by 1,849
Three-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971 · cited 1×
“Moreover, HepG2 cells have a PNPLA3 I148M mutation that was identified as a factor of genetic susceptibility in NAFLD patients 48,49 .”
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00980-1 · Cited by 897
Organ-on-a-chip: recent breakthroughs and future prospects
Wu, Q., Liu, J., Wang, X., Feng, L., Wu, J., Zhu, X., Wen, W., & Gong, X. (2020) · BioMedical Engineering OnLine · doi:10.1186/s12938-020-0752-0 · Cited by 701
Ricchi, M., Odoardi, M. R., Carulli, L., Anzivino, C., Ballestri, S., Pinetti, A., Fantoni, L. I., Marra, F., Bertolotti, M., Banni, S., et al. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05733.x · Cited by 645 · cited 1×
“OA has been reported to be more steatosis-inducing than PA, while PA is more cytotoxic than OA in hepatocyte 2D cultures 38 .”
Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes
Joshi-Barve, S., Barve, S. S., Amancherla, K., Gobejishvili, L., Hill, D., Cave, M., Hote, P., & McClain, C. J. (2007) · Hepatology · doi:10.1002/hep.21752 · Cited by 406 · cited 2×
“HepG2 OOCs are likely less sensitive to PA exposure for inducing TAG synthesis than 2D HepG2 cultures in which PA increases TAG accumulation 33–35 .”
Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide
Van Herck, M., Vonghia, L., & Francque, S. (2017) · Nutrients · doi:10.3390/nu9101072 · Cited by 392
Cited by
Application of Artificial Intelligence at All Stages of Bone Tissue Engineering
Kolomenskaya, E. R., Butova, V. V., Poltavskiy, A. V., Soldatov, A. V., & Butakova, M. A. (2023) · Biomedicines · doi:10.3390/biomedicines12010076 · Cited by 66
“This While this concept was widely applied to such organs as lungs, intestines, liver, kidneys, and others [143–145], applying it to bone tissues is still challenging. bone-on-a-chip platform was further applied to test anti-SOST antibody drugs using an AI-based image analysis system. β -catenin,…”
Qi, L., Gröger, M., Sharma, A., Goswami, I., Chen, E., Zhong, F., Ram, A., Healy, K. E., Hsiao, E. C., Willenbring, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52258-w · Cited by 54
Modeling cancer–microbiome interactions in vitro: A guide to co‐culture platforms
Moskal, K., Khurana, N., Siegert, L., Lee, Y., Clevers, H. C., Elinav, E., & Puschhof, J. (2024) · International Journal of Cancer · doi:10.1002/ijc.35298 · Cited by 25
“Such OOC plates are commercially available in both 2-channel and 3-channel formats 73,74 and recently another architecture with two vascular channel surrounding a third compartment where spheroids or organoids can be seeded in the ECM-like gel was proposed.”
Leslie, J., Krishnamurthy, K. A., Gopalsamy, I. K., Inácio, P., Huch, M., Gallage, S., Oakley, F., & Vacca, M. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01162-9 · Cited by 30
Rho, H. K., Kim, S., Kim, S. U., Kim, J. W., Lee, S. H., Park, S., Escorcia, F. E., Chung, J., & Song, J. (2024) · Nature Communications · doi:10.1038/s41467-024-53002-0 · Cited by 21
“Increased lipid droplet levels may lead to lipo-toxicity, resulting in increased in fl ammation-and fi brosis-related gene expressions 39,40 .”
Metadata
- Authors
- Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K.
- Affiliations
- Mahidol University (TH)
- Corresponding author
- Muta, Kenjiro
- Venue
- Scientific Reports
- Published
- 2023-10-09
- Volume
- 13
- Issue
- 1
- Pages
- 17019-17019
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC10562420
- OpenAlex
- W4387451531
- Cited by
- 29
- References
- 56
- Citations by year
- 2026: 15 · 2025: 6 · 2024: 7 · 2023: 1
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- The Program Management Unit for Competitiveness (C10F640323)
- The National Research Council of Thailand (NRCT383/2563)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- hepatic steatosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, HepG2 cells, fatty acid overload, cell viability, albumin synthesis, pioglitazone, elafibranor, drug screening
- MeSH terms
- Microphysiological Systems, Albumins, Humans, Inflammation, Liver, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip. https://app.cochat.ai/papers/10.1038/s41598-023-44198-0
- The paper
- Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023). A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip. Scientific Reports. https://doi.org/10.1038/s41598-023-44198-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.